// App-Quantinova.ai

TPS4140 : KEYNOTE-181: phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma.

Researchers

Presenter

  • Toshihiko Doi

Principal Investigators

  • Jaafar Bennouna

  • Lin Shen

  • Peter C. Enzinger

  • Ruixue Wang

  • Ildiko Csiki

  • Minori Koshiji

  • Manish A. Shah

Medical Centers

  • National Cancer Center Hospital, Tokyo, Japan

  • Institut de Cancerologie de l'Ouest Paul Papin, Angers, France

  • Peking University Cancer Hospital & Institute, Beijing, China

  • Dana-Farber Cancer Institute, Boston, MA

  • MSD China, Beijing, China

  • Merck & Co., Inc., Kenilworth, NJ

  • Merck & Co. Inc., Rahway, NJ

  • Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY

Locations

  • France

  • China

  • Japan

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Esophageal Cancer

  • Squamous cell carcinoma

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Pembrolizumab

  • Trastuzumab

  • Irinotecan

  • Paclitaxel

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • NCT02564263

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved